ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

18.19

-0.76 (-4.01%)

Sep 16, 2025, 4:00 PM EDT - Market closed

ArriVent BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-136.79	-80.49	-69.33	-36.91	-68.81
Asset Writedown & Restructuring Costs	-	-	-	-	57.21
Stock-Based Compensation	7.4	3.21	0.9	0.42	0.07
Change in Accounts Payable	0.25	-0.75	1.38	2.8	0.39
Change in Other Net Operating Assets	2.71	7.82	11.22	-9.95	-5.65
Operating Cash Flow	-126.63	-70.21	-55.84	-43.63	-16.78
Sale (Purchase) of Intangibles	-	-	-	-	-53.33
Investment in Securities	-141.73	-192.47	-	-	-
Investing Cash Flow	-141.73	-192.47	-	-	-53.33
Total Debt Issued	-	-	-	-	0.27
Total Debt Repaid	-	-	-	-	-0.27
Issuance of Common Stock	82.81	186.58	0.35	0.02	0
Other Financing Activities	-0.35	-	-2.41	-	-
Financing Cash Flow	82.46	186.58	42.86	169.72	119.82
Net Cash Flow	-185.9	-76.1	-12.98	126.09	49.71
Levered Free Cash Flow	-57.34	-48.64	-32.8	-29.81	-
Unlevered Free Cash Flow	-57.34	-48.64	-32.8	-29.81	-
Change in Working Capital	2.95	7.07	12.6	-7.15	-5.25

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q